@article{2ee2a44c646344f68c6e0efcf7995458,
title = "miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis",
abstract = "Cognitive deficits strongly affect the quality of life of patients with multiple sclerosis (MS). However, no cognitive MS biomarkers are currently available. Extracellular vesicles (EVs) contain markers of parental cells and are able to pass from the brain into blood, representing a source of disease biomarkers. The aim of this study was to investigate whether small non-coding microRNAs (miRNAs) targeting synaptic genes and packaged in plasma EVs may reflect cognitive deficits in MS patients. Total EVs were precipitated by Exoquick from the plasma of twenty-six cognitively preserved (CP) and twenty-three cognitively impaired (CI) MS patients belonging to two independent cohorts. Myeloid EVs were extracted by affinity capture from total EVs using Isolectin B4 (IB4). Fourteen miRNAs targeting synaptic genes were selected and measured by RT-PCR in both total and myeloid EVs. Myeloid EVs from CI patients expressed higher levels of miR-150-5p and lower levels of let-7b-5p compared to CP patients. Stratification for progressive MS (PMS) and relapsing-remitting MS (RRMS) and correlation with clinical parameters suggested that these alterations might be attributable to cognitive deficits rather than disease progression. This study identifies miR-150-5p and let-7b-5p packaged in blood myeloid EVs as possible biomarkers for cognitive deficits in MS.",
keywords = "biomarkers, cognitive deficits, microRNAs, multiple sclerosis, myeloid extracellular vesicles, plasma extracellular vesicles",
author = "Federica Scaroni and Caterina Visconte and Maria Serpente and Golia, {Maria Teresa} and Martina Gabrielli and Marijn Huiskamp and Hulst, {Hanneke E.} and Tiziana Carandini and {de Riz}, Milena and Anna Pietroboni and Emanuela Rotondo and Elio Scarpini and Daniela Galimberti and Teunissen, {Charlotte E.} and {van Dam}, Maureen and {de Jong}, {Brigit A.} and Chiara Fenoglio and Claudia Verderio",
note = "Funding Information: Conflicts of Interest: C.E.T. has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, and performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama and Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is the editor of a Neuromethods book, Springer. Funding Information: The work has been supported by FOE (Fondo Ordinario Enti di ricerca) 2022 and FISM? Fondazione Italiana Sclerosi Multipla?cod. 2018/R/22 to Claudia Verderio and 2016/B/2 to M.G., and financed or co-financed with the ?5 per mille? public funding. F.S. was the recipient of a fellowship from Regione Lombardia ?NeOn?, POR-FESR 2014?2020, ID 239047. M.S. is supported by MoH, grant GR-2019-12369100. Funding Information: Funding: The work has been supported by FOE (Fondo Ordinario Enti di ricerca) 2022 and FISM— Fondazione Italiana Sclerosi Multipla—cod. 2018/R/22 to Claudia Verderio and 2016/B/2 to M.G., and financed or co-financed with the {\textquoteleft}5 per mille{\textquoteright} public funding. F.S. was the recipient of a fellowship from Regione Lombardia “NeOn”, POR-FESR 2014–2020, ID 239047. M.S. is supported by MoH, grant GR-2019-12369100. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2022",
month = may,
day = "1",
doi = "https://doi.org/10.3390/cells11091551",
language = "English",
volume = "11",
journal = "Cells",
issn = "2073-4409",
publisher = "MDPI Multidisciplinary Digital Publishing Institute",
number = "9",
}